Key result
Elevated CHG index linked to ~2.7-fold higher risk of post-ablation AF recurrence.
Why the study?
High post-procedural recurrence after radiofrequency catheter ablation for atrial fibrillation limits long-term benefit, necessitating cost-effective preoperative biomarkers for individualized risk stratification.
Does the cholesterol-HDL-glucose (CHG) index predict atrial fibrillation recurrence in patients with non-valvular atrial fibrillation undergoing radiofrequency catheter ablation?
Cohort (n=625)
No
Does the cholesterol-HDL-glucose (CHG) index predict atrial fibrillation recurrence in patients with non-valvular atrial fibrillation undergoing radiofrequency catheter ablation?
Hazard Ratio: 2.713 (95% CI 1.917–3.839)
p-value: p=<0.001
The CHG index independently predicts AF recurrence after radiofrequency catheter ablation, and its addition to traditional risk models significantly improves prognostic accuracy.
May improve post-RFCA AF recurrence risk stratification; hypothesis-generating and requires prospective validation before practice change.
Aims Radiofrequency catheter ablation (RFCA) is a primary rhythm-control therapy for atrial fibrillation (AF), yet high post-procedural recurrence limits its long-term benefit. Cost-effective preoperative biomarkers are required to refine individualized risk stratification. This study evaluated the predictive performance of the cholesterol‑HDL‑glucose (CHG) index for AF recurrence after RFCA. Methods This retrospective cohort included 625 consecutive patients with non-valvular AF who received initial RFCA (2020–2024) and had complete 12-month follow-up. Subjects were divided into recurrence and non-recurrence groups. Multivariate Cox regression identified independent predictors of recurrence. ROC curves quantified the CHG index’s predictive power and optimal cut-off. Kaplan–Meier, restricted cubic spline (RCS), DeLong test, continuous NRI, IDI, and DCA were adopted to assess its linear association and incremental prognostic value. Subgroup interaction analyses further validated predictive consistency across clinical subgroups. Results The 12-month AF recurrence rate was 28.2% (176/625). The CHG index emerged as an independent recurrence risk factor, with an AUC of 0.698 (95% CI 0.651–0.745) and an optimal cut-off of 5.20. Higher CHG index corresponded to elevated cumulative recurrence risk (Log-rank P < 0.001), and RCS confirmed an approximate linear correlation between CHG index and recurrence risk. Adding the CHG index to the baseline clinical model significantly improved prediction (IDI = 0.092, continuous NRI = 0.542; both P < 0.001). Subgroup interactions existed for age, hypertension, and diabetes (all interaction P < 0.05). Conclusion The CHG index independently predicts post-RFCA AF recurrence. Adding the CHG index to traditional risk models improves discrimination and risk stratification, supporting its clinical utility for personalized recurrence evaluation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Non-valvular atrial fibrillation (n=625). Cholesterol-HDL-glucose (CHG) index vs. Low CHG index was evaluated on Atrial fibrillation recurrence at 12 months (HR 2.713, 95% CI 1.917-3.839, p=<0.001). An elevated CHG index (≥5.20) was independently associated with a higher risk of atrial fibrillation recurrence after radiofrequency catheter ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: